Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Best Stocks Under $5 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $5.00 (5 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Ur Energy stock logo

1. Ur Energy NYSEAMERICAN:URG

$0.81 0.00 (-0.59%)
Closing price 10/23/2026 04:10 PM Eastern
Extended Trading
$0.82 +0.01 (+1.13%)
As of 10/23/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur Energy

Market Capitalization
$325.21 million
Consensus Rating
Buy
Consensus Price Target
$2.28 (+181.2% Upside)
Volume
10.64 million shares
Average Volume
10.45 million shares
Today's Range
$0.79
▼
$0.83
Aclaris Therapeutics stock logo

2. Aclaris Therapeutics NASDAQ:ACRS

$3.75 -0.08 (-2.09%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$3.76 +0.00 (+0.13%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris Therapeutics

Market Capitalization
$535.53 million
Consensus Rating
Buy
Consensus Price Target
$11.33 (+202.2% Upside)
Volume
2.29 million shares
Average Volume
3.91 million shares
Today's Range
$3.68
▼
$3.85
Nouveau Monde Graphite stock logo

3. Nouveau Monde Graphite NYSE:NMG

$0.94 +0.05 (+6.16%)
Closing price 10/23/2026 03:58 PM Eastern
Extended Trading
$0.95 +0.00 (+0.21%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nouveau Monde Graphite Inc engages in the acquisition, exploration, development, and evaluation of mineral properties in Quebec, Canada. More about Nouveau Monde Graphite

Market Capitalization
$292.69 million
Consensus Rating
Buy
Consensus Price Target
$3.87 (+310.0% Upside)
Volume
304,251 shares
Average Volume
541,174 shares
Today's Range
$0.87
▼
$0.95
Cronos Group stock logo

4. Cronos Group NASDAQ:CRON

$3.35 -0.09 (-2.62%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$3.34 0.00 (-0.15%)
As of 10/23/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cronos Group Inc operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. More about Cronos Group

Market Capitalization
$1.27 billion
P/E Ratio
16.75
Consensus Rating
Buy
Consensus Price Target
$2.30 (-31.3% Downside)
Volume
816,778 shares
Average Volume
927,337 shares
Galiano Gold stock logo

5. Galiano Gold NYSEAMERICAN:GAU

$2.00 -0.09 (-4.31%)
Closing price 10/23/2026 04:10 PM Eastern
Extended Trading
$2.03 +0.03 (+1.50%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Galiano Gold Inc engages in the exploration and evaluation of gold properties in Canada. Its flagship asset is the Asanko Gold Mine that covers an area of approximately 21,000 hectares located in Ghana, West Africa. More about Galiano Gold

Market Capitalization
$547.69 million
P/E Ratio
7.69
Consensus Rating
Buy
Consensus Price Target
$3.85 (+92.5% Upside)
Volume
1.55 million shares
Average Volume
2.70 million shares
Niagen Bioscience stock logo

6. Niagen Bioscience NASDAQ:NAGE

$2.43 -0.09 (-3.57%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$2.48 +0.05 (+2.22%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. More about Niagen Bioscience

Market Capitalization
$200.70 million
P/E Ratio
13.50
Consensus Rating
Buy
Consensus Price Target
$10.33 (+325.2% Upside)
Volume
543,163 shares
Average Volume
594,170 shares
B2Gold stock logo

7. B2Gold NYSEAMERICAN:BTG

$4.78 -0.09 (-1.85%)
As of 10/23/2026 04:10 PM Eastern

B2Gold Corp. operates as a gold producer company. It operates the Fekola Mine in Mali, the Masbate Mine in the Philippines, and the Otjikoto Mine in Namibia. More about B2Gold

Market Capitalization
$6.42 billion
P/E Ratio
8.69
Consensus Rating
Buy
Consensus Price Target
$6.81 (+42.5% Upside)
Volume
24.85 million shares
Average Volume
19.63 million shares
Lexeo Therapeutics stock logo

8. Lexeo Therapeutics NASDAQ:LXEO

$2.80 -0.09 (-3.11%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$2.80 0.00 (0.00%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. More about Lexeo Therapeutics

Market Capitalization
$237.11 million
Consensus Rating
Buy
Consensus Price Target
$16.43 (+486.7% Upside)
Volume
619,382 shares
Average Volume
1.93 million shares
Today's Range
$2.73
▼
$2.97
Inventiva stock logo

9. Inventiva NASDAQ:IVA

$3.71 +0.11 (+3.06%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$3.68 -0.03 (-0.89%)
As of 10/23/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. More about Inventiva

Market Capitalization
$856.75 million
Consensus Rating
Buy
Consensus Price Target
$15.86 (+327.4% Upside)
Volume
4.71 million shares
Average Volume
3.38 million shares
Today's Range
$3.47
▼
$3.76
Taysha Gene Therapies stock logo

10. Taysha Gene Therapies NASDAQ:TSHA

$3.96 -0.05 (-1.25%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$3.88 -0.08 (-1.92%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. More about Taysha Gene Therapies

Market Capitalization
$1.30 billion
Consensus Rating
Buy
Consensus Price Target
$12.77 (+222.5% Upside)
Volume
2.59 million shares
Average Volume
4.84 million shares
Today's Range
$3.76
▼
$3.98
Palisade Bio stock logo

11. Palisade Bio NASDAQ:PALI

$1.33 -0.02 (-1.48%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$1.34 +0.00 (+0.38%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More about Palisade Bio

Market Capitalization
$235.26 million
Consensus Rating
Buy
Consensus Price Target
$9.29 (+598.2% Upside)
Volume
1.15 million shares
Average Volume
2.73 million shares
Today's Range
$1.28
▼
$1.37
iBio stock logo

12. iBio NASDAQ:IBIO

$0.72 -0.07 (-8.44%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$0.72 +0.00 (+0.59%)
As of 10/23/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBio

Market Capitalization
$50.42 million
Consensus Rating
Buy
Consensus Price Target
$6.00 (+735.9% Upside)
Volume
653,854 shares
Average Volume
864,608 shares
Today's Range
$0.71
▼
$0.78
Stereotaxis stock logo

13. Stereotaxis NYSEAMERICAN:STXS

$1.02 +0.02 (+2.20%)
Closing price 10/23/2026 04:10 PM Eastern
Extended Trading
$1.02 +0.00 (+0.49%)
As of 10/23/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about Stereotaxis

Market Capitalization
$100 million
Consensus Rating
Buy
Consensus Price Target
$3.50 (+243.1% Upside)
Volume
420,569 shares
Average Volume
590,727 shares
Today's Range
$0.99
▼
$1.04
Grab stock logo

14. Grab NASDAQ:GRAB

$2.79 -0.06 (-2.11%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$2.79 0.00 (-0.11%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grab Holdings Limited engages in the provision of superapps in Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. More about Grab

Market Capitalization
$11.68 billion
P/E Ratio
46.51
Consensus Rating
Buy
Consensus Price Target
$6.01 (+115.2% Upside)
Volume
43.02 million shares
Average Volume
63.90 million shares
Immuneering stock logo

15. Immuneering NASDAQ:IMRX

$3.73 -0.08 (-2.10%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$3.71 -0.02 (-0.64%)
As of 10/23/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. More about Immuneering

Market Capitalization
$246.50 million
Consensus Rating
Buy
Consensus Price Target
$15.71 (+321.3% Upside)
Volume
726,263 shares
Average Volume
714,369 shares
Today's Range
$3.59
▼
$3.78
Perspective Therapeutics stock logo

16. Perspective Therapeutics NYSEAMERICAN:CATX

$1.61 -0.65 (-28.76%)
Closing price 10/23/2026 04:10 PM Eastern
Extended Trading
$1.64 +0.03 (+2.17%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More about Perspective Therapeutics

Market Capitalization
$257.98 million
Consensus Rating
Buy
Consensus Price Target
$11.50 (+614.3% Upside)
Volume
5.60 million shares
Average Volume
1.70 million shares
Today's Range
$1.58
▼
$2.40
Compugen stock logo

17. Compugen NASDAQ:CGEN

$1.94 -0.02 (-1.02%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$1.96 +0.03 (+1.29%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. More about Compugen

Market Capitalization
$185.32 million
P/E Ratio
5.11
Consensus Rating
Buy
Consensus Price Target
$5.00 (+157.7% Upside)
Volume
148,020 shares
Average Volume
217,202 shares
Larimar Therapeutics stock logo

18. Larimar Therapeutics NASDAQ:LRMR

$2.35 +0.08 (+3.52%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$2.35 0.00 (0.00%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. More about Larimar Therapeutics

Market Capitalization
$235.81 million
Consensus Rating
Buy
Consensus Price Target
$10.33 (+339.7% Upside)
Volume
1.14 million shares
Average Volume
1.67 million shares
Today's Range
$2.22
▼
$2.37
Ovid Therapeutics stock logo

19. Ovid Therapeutics NASDAQ:OVID

$2.16 -0.21 (-8.86%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$2.15 -0.01 (-0.23%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid Therapeutics

Market Capitalization
$462.86 million
Consensus Rating
Moderate Buy
Consensus Price Target
$6.00 (+177.8% Upside)
Volume
2.02 million shares
Average Volume
1.70 million shares
Today's Range
$2.12
▼
$2.32
Equillium stock logo

20. Equillium NASDAQ:EQ

$1.23 -0.04 (-3.15%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$1.24 +0.01 (+0.41%)
As of 10/23/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. More about Equillium

Market Capitalization
$80.53 million
Consensus Rating
Moderate Buy
Consensus Price Target
$7.57 (+515.6% Upside)
Volume
315,633 shares
Average Volume
735,587 shares
Today's Range
$1.18
▼
$1.29
Inhibikase Therapeutics stock logo

21. Inhibikase Therapeutics NASDAQ:IKT

$1.59 -0.04 (-2.45%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$1.60 +0.01 (+0.63%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. More about Inhibikase Therapeutics

Market Capitalization
$227.44 million
Consensus Rating
Moderate Buy
Consensus Price Target
$4.75 (+198.7% Upside)
Volume
408,794 shares
Average Volume
636,549 shares
Today's Range
$1.54
▼
$1.65
Prime Medicine stock logo

22. Prime Medicine NASDAQ:PRME

$3.67 -0.06 (-1.61%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$3.54 -0.13 (-3.65%)
As of 10/23/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. More about Prime Medicine

Market Capitalization
$676.54 million
Consensus Rating
Moderate Buy
Consensus Price Target
$7.47 (+103.6% Upside)
Volume
4.56 million shares
Average Volume
5.17 million shares
Today's Range
$3.38
▼
$3.70
Opus Genetics stock logo

23. Opus Genetics NASDAQ:IRD

$3.47 -0.35 (-9.16%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$3.54 +0.06 (+1.87%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. More about Opus Genetics

Market Capitalization
$315.72 million
Consensus Rating
Moderate Buy
Consensus Price Target
$12.71 (+266.4% Upside)
Volume
1.12 million shares
Average Volume
1.72 million shares
Today's Range
$3.44
▼
$3.83
Adicet Bio stock logo

24. Adicet Bio NASDAQ:ACET

$3.99 -0.29 (-6.78%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$3.99 0.00 (0.00%)
As of 10/23/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More about Adicet Bio

Market Capitalization
$40.07 million
Consensus Rating
Moderate Buy
Consensus Price Target
$37.80 (+847.4% Upside)
Volume
162,965 shares
Average Volume
351,595 shares
Today's Range
$3.96
▼
$4.29
Cabaletta Bio stock logo

25. Cabaletta Bio NASDAQ:CABA

$1.47 -0.05 (-3.29%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$1.49 +0.02 (+1.50%)
As of 10/23/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. More about Cabaletta Bio

Market Capitalization
$257.71 million
Consensus Rating
Moderate Buy
Consensus Price Target
$15.60 (+961.2% Upside)
Volume
3.99 million shares
Average Volume
5.05 million shares
Today's Range
$1.39
▼
$1.50

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas